Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has announced the appointment of Dan Kirby as the company's Chief Commercial Officer. This newly created role is effective as of February 10, 2025. Prior to joining Iovance, Kirby led global commercial strategy for an emerging cell therapy platform of products as Chief Commercial Officer of Orca Bio. From 2018 to 2020, he served as Chief Commercial Officer at Omeros Corporation (NASDAQ: OMER), overseeing U.S. and EU launch readiness for Narsoplimab, a lectin pathway inhibitor, for hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Kirby's strengths include market engagement, reimbursement landscape evaluation, value story creation, key opinion leader outreach, communications, and advocacy. He expressed his enthusiasm for joining Iovance at a pivotal time as the company catalyzes and expands the commercial launch of Amtagvi and the growth of Proleukin in the U.S. and beyond.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. The company's Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. Iovance is committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve the lives of patients with cancer. Today the company's shares have moved -6.2% to a price of $5.34. For more information, read the company's full 8-K submission here.
